Sign in
Taking people in United StatesPhase 1/2

Tests CC-92480 combinations in adults with relapsed or refractory multiple myeloma

Tests CC-92480 with other drugs in adults with returning or resistant multiple myeloma.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Baltimore, Birmingham, Boston, Hackensack, and New York, United StatesSee the 5 sitesAlso in 4 other countries, 12 sites
Registry title
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Status
Recruiting
Phase
Phase 1/2
People taking part
260 people, planned
Started
18 Oct 2022
Planned end
12 Oct 2026
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CC-92480
  • Tazemetostat
  • BMS-986158
  • Trametinib
  • Dexamethasone
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or stopped responding to earlier treatment. It tests CC-92480 (BMS-986348) in combination with other drugs.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Relapsed or refractory multiple myeloma with documented progression during or after the last myeloma treatment. Measurable disease is needed. In Part 1, people must not respond to, cannot tolerate, or are not a candidate for established therapies. In Part 2, people must have relapsed after or not responded to the protocol-specified number of prior lines of therapy.
Earlier treatment
In Part 2, prior treatment must include an immunomodulatory drug (IMiD), a proteasome inhibitor, an anti-CD38 antibody and a T-cell redirecting therapy, unless the person is not a candidate for the T-cell therapy. No earlier CC-92480. In Part 2, no earlier tazemetostat, BMS-986158 or trametinib.

Main reasons for not taking part

  • Current or past myeloma in the central nervous system
  • Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or clinically significant light-chain amyloidosis
  • Impaired heart function or clinically significant heart disease
  • Earlier allogeneic stem-cell transplant, or autologous stem-cell transplant within 12 weeks of starting treatment
  • Recent SARS-CoV-2 infection (within 14 or 28 days before Cycle 1 Day 1) or COVID-19 vaccine within 14 days

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Relapsed or refractory multiple myeloma (MM) and must:; Have documented disease progression during or after their last myeloma therapy; For Part 1 Dose Finding: Be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM; For Part 2 Dose Expansion: Be refractory to or have relapsed after the protocol specified number of prior lines of therapy that include an immunomodulatory drug (IMiD), a proteasome inhibitor, an anti-CD38 mAb, and a T-cell redirecting therapy (TRT, eg, a CAR-T or T-cell engaging bispecific treatment) unless the participant is not a candidate for TRT
  • Must have measurable disease
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  • Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)

Who cannot take part

  • Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
  • For Part 1: received prior therapy with CC-92480
  • For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
  • Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
  • Received any of the following within 14 days prior to initiating study treatment:; Plasmapheresis; Major surgery; Radiation therapy other than local therapy for myeloma associated bone lesions; Use of any systemic anti-myeloma drug therapy
  • Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
  • COVID-19 vaccine within 14 days prior to C1D1; Other protocol-defined inclusion/exclusion criteria apply
  • Known active or history of central nervous system (CNS) involvement of MM
  • Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis
  • Impaired cardiac function or clinically significant cardiac disease

Where in United States

Also in 4 other countries, 12 sites

  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer CenterBaltimore, United StatesContact: Syed Abbas Ali, Site 0015Taking people
  • UAB Comprehensive Cancer CenterBirmingham, United StatesContact: Luciano Costa, Site 0002Taking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Monique Hartley-Brown, Site 0010Taking people
  • John Theurer Cancer Center At Hackensack UMCHackensack, United StatesContact: David Siegel, Site 0013Taking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Saad Usmani, Site 0007Taking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

The 6 groups in the trial

  • Part 1 Arm A: Dose FindingTreatment being tested

    Treatment: CC-92480, Tazemetostat, and Dexamethasone

  • Part 1 Arm B: Dose FindingTreatment being tested

    Treatment: CC-92480, BMS-986158, and Dexamethasone

  • Part 1 Arm C: Dose FindingTreatment being tested

    Treatment: CC-92480, Trametinib, and Dexamethasone

  • Part 2 Arm D: Dose ExpansionExisting treatment, for comparison

    Treatment: CC-92480 and Dexamethasone

  • Part 2 Arm E: Dose ExpansionTreatment being tested

    Treatment: CC-92480, Tazemetostat, and Dexamethasone

  • Part 2 Arm G: Dose ExpansionTreatment being tested

    Treatment: CC-92480, Trametinib, and Dexamethasone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Plain-language title
Tests CC-92480 combinations in adults with relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 September 2025